구독하기
연구 모델
서비스
전임상 효능 평가
Resource
Gla KO Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
Gla KO Mouse
제품명
Gla KO Mouse
제품 ID
I001223
품종 계통
C57BL/6NCya-Glaem1/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “Gla KO Mouse (카탈로그 번호 I001223)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
Disease Animal Models
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
Disease Animal Models
기본 정보
검증 데이터
관련 자료
기본 정보
유전자명
유전자 별칭
Ags
NCBI ID
염색체
Chr X
MGI ID
Datasheet
품종 계통 설명
Fabry Disease (FD) is a rare genetic lysosomal storage disorder caused by mutations in the GLA gene on the X chromosome, leading to a deficiency in lysosomal α-galactosidase A (α-GalA) activity. The absence of α-GalA results in the accumulation of the metabolic substrate globotriaosylceramide (GL3) in multiple organs, ultimately causing organ damage. In severe cases, this may lead to cardiovascular complications, end-stage renal disease, and even early death [1]. Clinically, FD is divided into early-onset (typical) and late-onset (attenuated) forms. Early-onset patients almost completely lose α-GalA activity and experience multi-organ damage early in life, while late-onset patients retain some enzyme activity, with symptom severity dependent on the residual enzyme activity [1-2]. Since the GLA gene is located on the X chromosome, male patients typically experience more severe symptoms. Current treatment options include enzyme replacement therapy (ERT) and molecular chaperone therapy (migalastat), but due to high costs and various limitations on efficacy, new therapeutic strategies are urgently needed [3]. In preclinical studies, Gla knockout (KO) mice have become the "gold standard" for studying the mechanisms of FD and evaluating therapies [4]. Gla KO mice exhibit GL3 accumulation in various tissues with aging, and their histological changes closely mimic the pathological features seen in human FD patients. It is widely used in research on enzyme replacement therapy, AAV gene therapy, and substrate reduction therapy [5-13].
This strain is a Gla gene knockout (KO) mouse model of Fabry Disease, created using gene editing technology to knockout the Gla gene on the X chromosome of mice (the homolog of the human GLA gene). The deletion of the Gla gene results in the absence of Gla gene expression and α-GalA activity. This model can be widely used for studying the mechanisms of Fabry Disease, assessing the efficacy and safety of potential therapies, and investigating lysosomal-related metabolic disorders and their pathophysiological effects.
Reference
Chan B, Adam DN. A Review of Fabry Disease. Skin Therapy Lett. 2018 Mar;23(2):4-6.
Lerario S, Monti L, Ambrosetti I, Luglio A, Pietra A, Aiello V, Montanari F, Bellasi A, Zaza G, Galante A, Salera D, Capelli I, La Manna G, Provenzano M. Fabry disease: a rare disorder calling for personalized medicine. Int Urol Nephrol. 2024 Apr 13.
Lenders M, Brand E. Fabry disease - a multisystemic disease with gastrointestinal manifestations. Gut Microbes. 2022 Jan-Dec;14(1):2027852.
Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, Kulkarni AB. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2540-4.
4D molecular therapeutics. An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adult Males with Fabry Disease. Retrieved April 18, 2024, from 4DMT PPT Template (4dmoleculartherapeutics.com)
Jeyakumar JM, Kia A, Tam LCS, McIntosh J, Spiewak J, Mills K, Heywood W, Chisari E, Castaldo N, Verhoef D, Hosseini P, Kalcheva P, Cocita C, Miranda CJ, Canavese M, Khinder J, Rosales C, Hughes D, Sheridan R, Corbau R, Nathwani A. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Gene Ther. 2023 Jun;30(6):487-502.
Shen JS, Arning E, West ML, Day TS, Chen S, Meng XL, Forni S, McNeill N, Goker-Alpan O, Wang X, Ashcraft P, Moore DF, Cheng SH, Schiffmann R, Bottiglieri T. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease. Hum Mol Genet. 2017 Mar 15;26(6):1182-1192.
uniQure. Patient enrollment in the clinical trial of AMT-191, uniQure’s gene therapy candidate for the treatment of Fabry disease, is expected to begin in the first half of 2024. Retrieved April 18, 2024, from Fabry Disease | Programs & Pipeline | uniQure
Pagant S, Huston MW, Moreira L, Gan L, St Martin S, Sproul S, Holmes MC, Meyer K, Wechsler T, Desnick RJ, Yasuda M. ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice. Mol Ther. 2021 Nov 3;29(11):3230-3242.
Yasuda M, Huston MW, Pagant S, Gan L, St Martin S, Sproul S, Richards D, Ballaron S, Hettini K, Ledeboer A, Falese L, Cao L, Lu Y, Holmes MC, Meyer K, Desnick RJ, Wechsler T. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Mol Ther Methods Clin Dev. 2020 Jul 9;18:607-619.
Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H, Kase R, Kobayashi T, Hashimoto Y, Shimada T. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13777-82.
PR Newswire. CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress. Retrieved April 18, 2024, from CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress (prnewswire.com)
Ziegler RJ, Cherry M, Barbon CM, Li C, Bercury SD, Armentano D, Desnick RJ, Cheng SH. Correction of the Biochemical and Functional Deficits in Fabry Mice Following AAV8-mediated Hepatic Expression of α-galactosidase A. Mol Ther. 2007 Mar;15(3):492-500.
변형 전략
Exons 2-5 of the Gla gene in the mouse X chromosome were knocked out using gene editing technology.

Figure 1. Gene editing strategy of Gla KO mice.
응용 분야
Mechanistic studies and therapeutic evaluations of Fabry Disease (FD);
Research on α-GalA function and related metabolic pathways;
Studies on lysosomal structure and function, and exploration of diseases caused by lysosomal defects.
검증 데이터
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
